1. PSA response (Time Frame - up to 10 years): Best PSA response and PSA response after 3 months from start of radionuclide therapy
2. PSA-PFS (Time Frame - up to 10 years): PSA-based progression-free survival (PFS) according to PCWG3 criteria. From date of start of radionuclide therapy until documented and confirmed PSA-progression
3. OS (Time Frame - up to 10 years): Overall survival. From date of start of radionuclide therapy until the date of death from any cause assessed
4. Toxicity (adverse events) (Time Frame - up to 10 years): All toxicity occurring after start of radionuclide treatment will be registered according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.03).
5. Toxicity-related discontinuation of radionuclide treatment (Time Frame - up to 10 years): Rate of toxicity-related discontinuation of radionuclide therapy
Secondary outcome:
1. Conventional imaging response (Time Frame - up to10 years): Response to radionuclide therapy based on conventional imaging according to RECIST 1.1
2. Molecular imaging response (Time Frame - up to 10 years): Response to radionuclide therapy based on molecular imaging
3. Quality-of-life in patients receiving radionuclide therapy (Time Frame - up to 10 years): Quality-of-life assessed from start of radionuclide treatment by EORTC QLQ-C30 questionaires
4. Pain control achieved by radionuclide therapy (Time Frame - up to 10 years): Based on VAS-BPI patient questionaires from start of radionuclide treatment
5. Absorbed doses achieved by radionuclide therapy (Time Frame - up to 10 years): Absorbed doses in Gy/GBq based on intra- / posttherapeutic dosimetry when available
